BioLineRx
Services: Product Approval & Launch, Disease Awareness, Advocacy Relations, Executive Visibility, Scientific Comms, Internal Comms, Social Media
Media Materials
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade
Video Development
Internal Communications
